a Department of Nephrology , National Clinical Research Center of Kidney Disease, Jinling Hospital, Nanjing University School of Medicine , Nanjing , PR China.
b Department of Nephrology , The First Affiliated Hospital of Sun Yat-sen University , Guangzhou , PR China.
Curr Med Res Opin. 2018 Aug;34(8):1491-1500. doi: 10.1080/03007995.2018.1467886. Epub 2018 May 3.
With limited data available on calcification prevalence in chronic kidney disease (CKD) patients on dialysis, the China Dialysis Calcification Study (CDCS) determined the prevalence of vascular/valvular calcification (VC) and association of risk factors in Chinese patients with prevalent hemodialysis (HD) or peritoneal dialysis (PD).
CKD patients undergoing HD/PD for ≥6 months were enrolled. Prevalence data for calcification and medical history were documented at baseline. Coronary artery calcification (CAC) was assessed by electron beam or multi-slice computed tomography (EBCT/MSCT), abdominal aortic calcification (AAC) by lateral lumbar radiography, and cardiac valvular calcification (ValvC) by echocardiography. Serum phosphorus, calcium, intact parathyroid hormone (iPTH), and 25-hydroxyvitamin D and FGF-23 were evaluated. A logistic regression model was used to evaluate the association between risk factors and VC.
Of 1,497 patients, 1,493 (78.3% HD, 21.7% PD) had ≥1 baseline calcification image (final analysis cohort, FAC) and 1,423 (78.8% HD, 21.2% PD) had baseline calcification data complete (BCDC). Prevalence of VC was 77.4% in FAC (80.8% HD, 65.1% PD, p < .001) and 77.5% in BCDC (80.7% HD, 65.8% PD). The proportion of BCDC patients with single-site calcification were 20% for CAC, 4.3% for AAC, and 4.3% for cardiac valvular calcification (ValvC), respectively. Double site calcifications were 23.4% for CAC and AAC, 6.5% for CAC and ValvC, and 1.1% for AAC and ValvC, respectively. In total, 17.9% patients had calcification at all three sites.
High prevalence of total VC in Chinese CKD patients will supplement current knowledge, which is mostly limited, contributing in creating awareness and optimizing VC management.
由于关于透析慢性肾脏病(CKD)患者钙化患病率的数据有限,因此中国透析钙化研究(CDCS)确定了中国有症状血液透析(HD)或腹膜透析(PD)患者中血管/瓣膜钙化(VC)的患病率及其危险因素的相关性。
纳入接受 HD/PD 治疗≥6 个月的 CKD 患者。在基线时记录钙化和病史的患病率数据。通过电子束或多层计算机断层扫描(EBCT/MSCT)评估冠状动脉钙化(CAC),通过侧位腰椎射线照相评估腹主动脉钙化(AAC),通过超声心动图评估心脏瓣膜钙化(ValvC)。评估血清磷、钙、全段甲状旁腺激素(iPTH)、25-羟维生素 D 和 FGF-23。使用逻辑回归模型评估危险因素与 VC 之间的关联。
在 1497 名患者中,1493 名(78.3%HD,21.7%PD)具有≥1 个基线钙化图像(最终分析队列,FAC),1423 名(78.8%HD,21.2%PD)具有完整的基线钙化数据(BCDC)。FAC 中 VC 的患病率为 77.4%(80.8%HD,65.1%PD,p<0.001),BCDC 中 VC 的患病率为 77.5%(80.7%HD,65.8%PD)。BCDC 患者中 CAC、AAC 和心脏瓣膜钙化(ValvC)的单部位钙化比例分别为 20%、4.3%和 4.3%。CAC 和 AAC 的双部位钙化比例分别为 23.4%、CAC 和 ValvC 为 6.5%、AAC 和 ValvC 为 1.1%。总共有 17.9%的患者在所有三个部位均有钙化。
中国 CKD 患者的总 VC 患病率较高,这将补充目前主要限于的有限知识,有助于提高认识和优化 VC 管理。